Molecular Partners holds its R&D update in New York, entitled “The DARPin® Difference – Offering Patients a New Dimension of Protein Therapeutics”, which features a series of presentations highlighting the scientific rationale and the potential clinical impact of the DARPin® approach, as well as the company’s continued forward integration and evolution towards becoming a fully integrated biopharmaceutical company.
At the EGM the shareholders of Molecular Partners approved the election of William (Bill) Burns, former CEO of Roche Pharmaceuticals, and Patrick Amstutz, CEO of Molecular Partners, as new members of the Board of Directors with large majorities.
Molecular Partners announced its Interim Management Statement for the period ending September 30, 2017.
The first patient was dosed in the phase 1 clinical study of Molecular Partners’ oncology asset MP0274, a proprietary DARPin® drug candidate for the treatment of HER2-positive cancer with a new mode of action compared to current standard of care antibodies.
Molecular Partners published the invitation to EGM on October 31, 2017.
The Board of Directors of Molecular Partners has nominated William (Bill) Burns, former CEO of Roche Pharmaceuticals, for election to the Board at an EGM on October 31, 2017, after which the Board of Directors plans to appoint him Vice-Chairman. At the EGM Patrick Amstutz, CEO of Molecular Partners, also stands for election to the Board.
Molecular Partners published the invitation, preliminary agenda and additional information on its R&D update on “The DARPin® Difference – Offering Patients a New Dimension of Protein Therapeutics.” The event takes place in New York on November 9, 2017, 12.00-2.30 pm EDT.
Molecular Partners’ announced that its management team participates in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York.
Molecular Partners announced its results and highlights for H1 2017, a semester in which the company achieved two key clinical milestones: the completion of full enrollment in its two phase 3 clinical trials of abicipar in wet AMD, and the dosing of the first patient in the phase 2 trial of MP0250 in multiple myeloma. In addition, the company diversified its shareholder base through the acquisition of a substantial portion of the venture capital investors’ shareholdings by new private investors.
The first patient in the phase 2 Multiple Myeloma study was dosed and an IND submission to FDA is planned for MP0250 in EGFR-mutated Non-Small Cell Lung Cancer (EGFR mut NSCLC) in H2 2017.